What is Groman?
Established in 2003, Groman Inc. operates at the intersection of dental safety and medical device engineering. The company is best known for its patented AerosoLESS technology, a specialized solution designed to mitigate aerosol dispersion during high-risk clinical procedures. By prioritizing the safety of healthcare providers, Groman has carved out a distinct niche in the medical equipment market. Following the global health crisis, the firm demonstrated operational agility by diversifying its portfolio to include advanced respiratory personal protective equipment. Manufacturing remains centralized in a high-standard FDA-listed facility in South Florida, ensuring rigorous quality control and regulatory compliance as the company scales its distribution networks.
How much funding has Groman raised?
Groman has raised a total of $26K across 1 funding round:
Debt
$26K
Debt (2021): $26K with participation from PPP
Key Investors in Groman
PPP
Public-Private Partnership
What's next for Groman?
The infusion of capital positions Groman Inc. to transition from a specialized niche player to a broader provider of critical healthcare infrastructure. Strategic priorities for the upcoming fiscal periods include the expansion of its manufacturing capacity to meet rising demand for its AerosoLESS suite and the potential development of next-generation respiratory protection. As the company navigates this growth phase, management is expected to focus on deepening its penetration within the dental and surgical markets while leveraging its established supply chain to maintain competitive advantages in product efficacy and safety standards. The firm remains committed to continuous innovation, aiming to set new benchmarks for clinical environment safety.
See full Groman company page
